KNOWLEDGE BANK

Interviews

GE Healthcare

President & CEO
Our current business focus and strengths are in the areas of bioprocessing proteins cellular analysis cell handling and tools for cell therapy Our strategic intent is to add adjacent technologies or applications which can add value to the overall customer solutions we provide We are particularly excited about the sample collection and storage opportunity with the FTA product lineWe have a stron...

Articles

How Big Data is Transforming Clinical Trials in Asia

Clinical trials are the cornerstone of medical innovation providing the evidence needed to approve new treatments However these trials often encounter significant challenges particularly in Asia where healthcare landscapes are highly diverse Issues such as recruitment delays regulatory hurdles and resource limitations impede progress

Research Insights

Combining Machine Learning and Iterative Experiments to keep pace with Emerging Viral Variants of Concern

Modeling and predicting viral mutations before they emerge plays a crucial role in pandemic preparedness enabling the early identification of emerging variants of concern VOCs and guiding timely updates

Case Studies

Pharma Connects On Social: Top 20 Pharmaceutical Companies On Social Media

Abstract Pharmaceutical companies have taken a long time to start using social media in the first place but the industry is still struggling to fully embrace the digital space There are now more than two billion active social media users almost a third of the worlds population Customers are talking about health on the internet and in recent years s

Techno Trends

Telisotuzumab Vedotin (Teliso-V) Developed for the Treatment of Non-Small Cell Lung Cancer

AbbVie developed Telisotuzumab Vedotin TelisoV an investigational antibodydrug conjugate ADC to treat patients with nonsmall cell lung cancer NSCLC TelisoV is used to treat patients with advancedmetastatic epidermal growth factor receptor EGFR wild type nonsquamous nonsmall cell lung cancer NSCLC consisting

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Harnessing Plant Potential

Rishabh Rajkumar Jadhav

Rishabh Rajkumar Jadhav, who is developing antibacterial proteins to tackle antimicrobial resistance and received a SARTHI fellowship. Research Scholar. Currently working on plant bioengineering for therapeutic protein production. Working on Molecular biology techniques (Gene cloning, CRISPR-Cas), Plant tissue culture, and Microbiology.

 

Deepa Khare

Deepa Khare, an Associate Professor at Bennett University, holds a Ph.D. and postdoc in plant molecular biology from POSTECH, South Korea. She leads a project on plant-based biotherapeutics with her research scholar.

 

2

The Therapeutics Landscape of Miniproteins

Victor H Bustos

Victor H. Bustos, Ph.D., is the Vice President of Preclinical R&D at Ordaos Bio. A specialist in protein engineering with a doctorate in Biomedicine, he leads the design of AI-generated mini-proteins. Previously, he spent 17 years at Rockefeller University focusing on complex cellular mechanisms and therapeutic target validation.

Alena Romanova

Alena Romanova is a Scientist I at Ordaos Bio, where she develops experimental workflows for protein characterisation and biologics discovery, including the application of cell-free protein expression and biochemical assays.

3

Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery

Dr. Stevan Pecic

Dr. Stevan Pecic is an assistant professor at the Department of Chemistry and Biochemistry at California State University, Fullerton. His main research interests and assignments are focused on the identification of novel inhibitors of enzymes involved in lipid metabolism and their evaluation as potential therapeutics in pain management.

 

Xiaohui Weng

Xiaohui Weng earned a bachelor’s in chemistry from Fordham University and recently completed her master’s degree working in Dr. Pecic medicinal chemistry lab at California State University, Fullerton. Her current research focuses on target identification for glioblastoma and the synthesis of new anti-cancer drugs.

 

Michael Gonzalez

Michael Gonzalez is a graduate student pursuing a master’s in chemistry at California State University Fullerton. Currently he also interns at a start-up biotech company, playing an important role in chemistry development for their high-throughput macrocyclic synthesis platform.

 

Arya Emami

Arya obtained his Hon. BSc. in Human kinetics from University of Guelph, where he completed a summer internship at Dr. Ghavami’s lab at University of Manitoba. Arya then pursued a double major from York University majoring in Neuropsychology. Arya’s research under the supervision of Dr. Ghavami resulted in four publications, and he has since been involved in the review and publication process of manuscripts in highly regarded journals. Arya is currently entering the second year of his Doctor of Dental Surgery program at the Faculty of Dentistry, University of Toronto.

Dr. Amir Barzegar Behrooz

Dr. Amir Barzegar Behrooz is a cancer researcher and postdoctoral fellow at the College of Pharmacy, University of Manitoba. His work focuses on various aspects of cancer biology, particularly glioblastoma. His work focuses on targeted cancer therapy, and theranostic targets in cancer cells via Onco-Multi-OMICS.

 

Dr. Rui Vitorino

Dr. Rui Vitorino, Principal Investigator at the University of Aveiro, specializes in OMICS, proteomics, and bioinformatics. His research on biofluids like saliva and urine aims to uncover disease pathways and biomarkers. Vitorino's multidisciplinary approach enhances early disease detection, influencing molecular and cell biology studies significantly.

 

Dr. Saeid Ghavami

Dr. Ghavami, an Associate Professor at the University of Manitoba, specializes in apoptosis, autophagy, and unfolded protein response regulation. With over 300 publications and numerous awards, he's globally recognised. Affiliated with institutions worldwide, he serves as Associate Editor for multiple scientific journals.

 

4

Computational Approach towards Designing Potent Inhibitors for Tuberculosis

Soumyadip Das

Soumyadip Das received a BSc degree from University of Calcutta, India, in 2017 and a MSc degree from Vellore Institute of Technology, Vellore, India, in 2019. He is currently pursuing his PhD degree from Vellore Institute of Technology, Vellore, India, under the supervision of Dr. Kaushik Chanda. His research interest includes diversity-oriented synthesis, anticancer drug design, and nanocatalysis.

 

Balamurali MM

Balamurali MM, was awarded the Master’s degree in Chemistry, by Madurai Kamaraj University, Tamil Nadu, India in 1999. He persuaded his doctoral research in Photophysical Chemistry at Indian Institute of Technology Kanpur, under the supervision of Prof. Sneh Kumar Dogra. In 2005, he was awarded the CSIR research associate fellowship and continued his postdoctoral research in Prof. Raghavan Varadarajan’s group at Indian Institute of Science Bangalore.

 

Kaushik Chanda

Kaushik Chanda, obtained his MSc in Organic Chemistry from Gauhati University, Assam India in 2001. Subsequently worked as a Senior Research Fellow in ICAR-NATP funded project in St Anthonys College, Shillong, India from 2002-2005. In 2006, he moved to Taiwan for pursuing PhD in Applied Chemistry from National Chiao Tung University under the guidance of Prof Chung Ming Sun on a topic of Combinatorial Chemistry.

 

5

Magnetic Nanoparticles and their Application Studies on Synthesis Characterisation

Prabhanjan S Giram

Prabhanjan S Giram qualified CSIR-NET AIR-81 in chemical sciences and received his Ph. D from National chemical laboratory, Pune. He Received Eudragit® 2018 Award of 1500 Euros from Evonik health care Germany. He also received newton Bhabha Fellowship from British council, UK and DBT, India. He has expertise in synthesis of biocompatible, biodegradable polymer with rationalised design of nanoformulation, nanofiber, semisolid dosage form such as ointment, creams, and gel.

 

Shubham R Musale

Shubham R Musale has graduate in pharmacy from Savitribai Phule Pune University. He got fellowship for M.pharm from AICTE. The Thesis titled for M.pharm Design of In-expensive Collector for preparation Electrospun Nanofiber. He has 2 review publication and 1 Book Chapter.

 

Sushil Y Raut

Sushil Y Raut has over 12 years of teaching and research experience. He has more than 25 research and review publications. He filed 3 Indian patents and over 20 national as well as international presentations in his credits. He is recipient of international research mobility fellowship and other prestigious awards.

 

press releasesRead more...

Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®

Sanofi has partnered with NBA Champion KarlAnthony Towns to help raise awareness about the importance of COVID vaccination among those eligible during the respiratory season

ALK expands strategic tablet supply partnership with Catalent

ALK ALKBDC Nasdaq Copenhagen ALK B today announced that it has expanded its longstanding contract manufacturing partnership with Catalent Inc Catalent a leader in enabling the development

Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month

Piramal Pharma Solutions PPS a leading global Contract Development and Manufacturing Organization CDMO and part of Piramal Pharma Ltd PPL NSE PPLPHARMA BSE

OnDosis and Adare Pharma Solutions Announce Strategic Collaboration to Advance OnDosis's Lead U.S. ADHD Program

OnDosis AB OnDosis a Swedish life science company developing drug device combinations for precision dosing of oral solid medicines based on the Dosage Manager device platform and Adare Pharma

Expert Shares Why ADC Development is Demanding a New Level of Bioconjugation Expertise

Antibodydrug conjugates have moved from a promising concept to one of the most actively developed drug classes in oncology Behind that progress lies a manufacturing challenge that is becoming more demanding by the year

Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596

Hengrui Pharma SH HK today announced that it has entered into a license agreement with Novo Nordisk Novo for HRS a phase Iready glucagonlike peptide receptor GLPR

EventsRead more...

05 - 06

Oct 2026

ISPSAI France 2026

Paris, France

05 - 08

Oct 2026

12 - 13

Oct 2026

Pharmaceutics 2026

Village Hotel Changi, Singapor...

12 - 13

Oct 2026

2nd International Conference on Drug Discovery

Village Hotel Changi, Singapor...

14 - 15

Oct 2026

PDA Aseptic Manufacturing Excellence Conference

Pullman East Melbourne, Austra...

21 - 23

Oct 2026

21 - 22

Oct 2026

22 - 23

Oct 2026

PDA Aseptic Symposium 2026

Congress Square Nakanoshima, O...

LATEST NEWSRead more...

Regeneron and Sanofi Expand Collaboration to Develop Long-Acting Immunology Antibodies

Regeneron Pharmaceuticals and Sanofi have expanded their longstanding antibody collaboration to develop and commercialise a new group of longacting immunology treatments

SK pharmteco Announces $200 Million Investment to Expand Manufacturing Capacity

SK pharmteco has announced a fiveyear investment of more than million to expand and upgrade its development and manufacturing capabilities in the US focusing on small molecules and peptides

CAS and Novartis Collaborate to Advance AI-Ready Reaction Data

CAS has announced a collaboration with Novartis Biomedical Research to improve access to reaction data and support the use of artificial intelligence in scientific research

AbbVie Partners with Valkai to Expand AI Use in Clinical Development

AbbVie has partnered with Valkai to expand the use of AI across selected areas of clinical development

Turbine and Daiichi Sankyo Expand ADC Discovery Collaboration

Turbine and Daiichi Sankyo have expanded their collaboration to support antibodydrug conjugate ADC discovery using computational modelling

TriSalus Receives FDA Clearance for TriNav Advance for Liver Embolisation

TriSalus Life Sciences has received k clearance from the US Food and Drug Administration FDA for TriNav Advance a new device within its PressureEnabled Drug Delivery PEDD portfolio for liverdirected embolisation procedures